#67 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Clinicians need to understand that cannabis psychosis risk increases with age, which contradicts common assumptions and should inform risk stratification during patient screening and counseling. Pharmacist-led post-discharge interventions represent an evidence-based approach to safer medicinal cannabis use that clinical teams can implement to improve patient outcomes and reduce adverse events. Parliamentary support for safer medicines practices creates an opportunity to establish standardized clinical protocols and evidence-based guidelines that currently lack consistency in cannabis prescribing across healthcare settings.
A newly established Parliamentary Friendship Group is advocating for safer medicines use, with particular attention to medicinal cannabis products and associated clinical risks including psychosis, which appears to increase with patient age. This regulatory and advocacy initiative underscores growing recognition among policymakers that medicinal cannabis requires careful clinical oversight and patient safety monitoring comparable to other pharmaceutical interventions. The group’s focus on pharmacist-led post-discharge interventions reflects evidence that structured medication management can improve outcomes and reduce adverse events in cannabis users. For clinicians, this parliamentary attention signals potential shifts toward clearer prescribing guidelines, standardized safety protocols, and better integration of pharmacy expertise in cannabis medicine practice. Patients using medicinal cannabis may increasingly benefit from coordinated care models that include pharmacist counseling and age-stratified risk assessment, particularly regarding psychosis vulnerability in older populations. Clinicians should anticipate evolving regulatory frameworks and consider incorporating pharmacist collaboration and enhanced monitoring, especially age-appropriate psychosis screening, into their cannabis prescribing practice.
“What’s encouraging here is the emphasis on structured, pharmacist-led oversight of cannabis as medicine, because we know from solid epidemiological data that age is a real risk modifier for psychosis-related adverse effects. That said, we still need more prospective trials in primary care settings to understand which patients benefit most and how to operationalize these safety protocols in routine practice.”
🏥 Parliamentary advocacy for safer medicinal cannabis use reflects growing recognition that cannabinoid therapies occupy an increasingly important but clinically complex niche in modern therapeutics. The age-related increase in psychosis risk documented in cannabis research is particularly salient given that older adults often have multiple comorbidities and polypharmacy concerns that complicate both the risk-benefit calculus and drug interaction profiles for cannabinoid products. Pharmacist-led post-discharge interventions represent a pragmatic approach to standardizing counseling around cannabis safety, though clinicians should remain cognizant that evidence for specific cannabinoid formulations and dosing regimens in many indications remains limited and heterogeneous. Healthcare providers prescribing or recommending cannabis products should systematically assess individual psychosis vulnerability (personal or family history), clarify whether evidence supports use for the specific indication, and emphasize the role of pharmacist monitoring as part of a coordinated care model
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
